Invivyd (IVVD) Cash & Current Investments (2020 - 2025)
Invivyd posted quarterly Cash & Current Investments of $226.7 million for Q4 2025, up 226.88% year-on-year from $69.3 million in Q4 2024, and up 166.8% on a QoQ basis from $85.0 million in Q3 2025.
Invivyd (IVVD) has 6 years of Cash & Current Investments data on file, last reported at $226.7 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Current Investments rose 226.88% year-over-year to $226.7 million; the trailing twelve-month figure through Dec 2025 stood at $226.7 million (up 226.88% YoY), and the FY2025 full-year result was $226.7 million, up 226.88% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $226.7 million, up from $85.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $542.2 million in Q4 2021 and bottomed at $34.9 million in Q2 2025.
- The 5-year median for Cash & Current Investments is $181.8 million (2023), against an average of $227.9 million.
- The widest annual swing landed in 2021, when Cash & Current Investments jumped 371.55%; it then slumped 83.02% in 2022.
- A 5-year view of Cash & Current Investments shows it stood at $542.2 million in 2021, then plunged by 83.02% to $92.1 million in 2022, then jumped by 117.91% to $200.6 million in 2023, then sank by 65.44% to $69.3 million in 2024, then soared by 226.88% to $226.7 million in 2025.
- The last three Cash & Current Investments figures came in at $226.7 million (Q4 2025), $85.0 million (Q3 2025), and $34.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 226.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 226.69 Mn |
| Sep 30, 2025 | 84.97 Mn |
| Jun 30, 2025 | 34.91 Mn |
| Mar 31, 2025 | 48.08 Mn |
| Dec 31, 2024 | 69.35 Mn |
| Sep 30, 2024 | 106.87 Mn |
| Jun 30, 2024 | 147.88 Mn |
| Mar 31, 2024 | 189.39 Mn |
| Dec 31, 2023 | 200.64 Mn |
| Sep 30, 2023 | 181.82 Mn |
| Jun 30, 2023 | 121.95 Mn |
| Mar 31, 2023 | 126.47 Mn |
| Dec 31, 2022 | 92.08 Mn |
| Sep 30, 2022 | 278.15 Mn |
| Jun 30, 2022 | 474.89 Mn |
| Mar 31, 2022 | 532.22 Mn |
| Dec 31, 2021 | 542.22 Mn |
| Sep 30, 2021 | 478.27 Mn |
| Jun 30, 2021 | 392.51 Mn |
| Dec 31, 2020 | 114.99 Mn |